ArticleFrontiers in veterinary science2026
Case Report: Clinical manifestations reported in a canine after ingesting ruxolitinib phosphate (Opzelura
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes a canine patient that developed cardiovascular and ocular abnormalities following ingestion of ruxolitinib phosphate 1.5% topical cream. The objective of this report is to characterize the exposure history, clinical presentation, diagnostic findings, therapeutic interventions, and to evaluate ruxolitinib phosphate within the context of its pharmacologic class, emphasizing similarities with related veterinary medications. Building on a recently published retrospective study of oclacitinib maleate overdoses, this case highlights shared clinical manifestations of ruxolitinib phosphate overdose and contributes to a broader understanding of JAK inhibitor toxicosis in veterinary medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.